Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of the Biologics License Application (BLA) for zanidatamab, the human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, for the treatment of previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary […]
Introducing Pride in Biotech
We’re excited to launch Pride in Biotech, a Vancouver-based community to empower lesbian, gay, bisexual, transgender, and queer professionals in the drug development industry through networking, education, advocacy, professional development, and peer support. Brought to you by Zymeworks, the inaugural Pride in Biotech event is led by our ZYME&Proud team and will take place on […]
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer Completed
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the HER2-targeted bispecific antibody zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). If […]
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
Zymeworks Announces Additional Leadership Appointments
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
Zymeworks Added to Nasdaq Biotechnology Index
Updated Phase 2a Data Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer Presented at SABCS 2023
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral […]
Zymeworks Announces Participation in Upcoming Investor Conference
